September 25, 2006

For Immediate Release

Markets for Surgical Devices for Tumor Ablation (MedMarkets)

FOOTHILL RANCH, CA The market for surgical devices to achieve ablation of cancerous tissue is growing rapidly. As innovative technologies make their way into the market, a growth rate of roughly 30% is expected annually over the next decade. This market is driven by advances in the areas of radio frequency ablation, targeted ablation, microwave and laser energy and cryosurgery, according to the September edition of MedMarkets from MedMarket Diligence.

Due to the advantages of using various energy types to necrose cancerous tissue via endoscopic or percutaneous delivery rather than open surgical technologies, particularly for prostate and liver tumors, sales of ablation technology are increasing at a rapid pace.  Cryoablation is first in ablation technology types making in-roads into cancer, with its ability to precisely localize energy (and minimize collateral damage) and a favorable decision by Medicare in support of ambulatory prostate cryotherapy two good reasons.

Radiofrequency ablation (RFA) follows in adoption for tumor ablation, also with an emphasis in prostate cancer.  RFA sales will demonstrate 25% annual growth rates, supported by continued expansion of RFA in prostate cancer and growth of the modality in other cancers.

The MedMarkets September 2006 edition addresses cryoablation, RFA, high intensity focused ultrasound (HIFU), and laser modalities used in treatment of cancer, detailing the products, technologies, and recent developments by companies in this industry.  Companies with recent developments in this field include Boston Scientific, BSD Medical, American Medical Systems, Focus Surgery, Endocare, InSightec, Inovio Biomedical, Integra LifeSciences, International Brachytherapy, North American Scientific, RITA Medical Sytems, Biocompatibles International, SenoRx, Xoft and others.

MedMarkets is published 12 times annually by MedMarket Diligence.  Coverage encompasses medical device, biotech, biomaterials and the range of technologies encompassing device market developments and analysis of Interventional Cardiology, Cardiovascular Surgery, Orthopedics/Musculoskeletal, Abdominal & Thoracic Surgery, Gynecology, Oncology, Neurology & Neurosurgery and other clinical sectors. Past coverage may be reviewed at www.mediligence.com/archive2006.html.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes the MedMarkets newsletter, a monthly analysis of the market implications of new medical technologies, and dedicated reports on technology markets.  For additional details, contact Patrick Driscoll at email or call 949-859-3401 or toll-free (in the U.S.). 1-866-820-1357.